What is a EudraCT form?
EudraCT form (concerns only the EU) The EudraCT form contains information on the clinical trial, the investigational medicinal product, the study design and the different actors involved (sponsor, applicant, CROs, central laboratories, investigators, etc.).
What types of studies does EU Ctr not apply to?
All phase 1 trials, conducted solely in adults and which are not part of a Paediatric Investigation Plan (PIP), are not public in the EU CTR. Please refer to European Guidance 2008/C 168/02 Art. 3 para 2 .
What is substantial amendment?
A substantial amendment is defined as change to the terms of the protocol or any other supporting documentation that is likely to affect to a significant degree: the safety or physical or mental integrity of participants. the scientific value of the research. the conduct or management of the research.
How long does it take to get a EudraCT number?
The response from the Competent Authority, whether the request for authorisation is positive or negative, could take up to 60 days. This number identifies the protocol for a trial, whether conducted at a single site or at multiple sites in one or more Member States.
Do I need a EudraCT number?
A EudraCT number is required in order to apply to the Medicines and Healthcare products Regulatory Agency (MHRA) for a Clinical Trial Authorisation (CTA) and to apply for REC approval of your clinical trial. CTIMPS which began before 2021 will still need to register and report results on EudraCT.
What is IND number in clinical trials?
An Investigational New Drug Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.
Who decides if an amendment is substantial or not?
the sponsor’s
It is the sponsor’s responsibility to decide whether an amendment is substantial or non-substantial. To help you with this categorisation, we have provided examples of substantial and non-substantial amendments.
When can a substantial amendment be made?
Section 14 of Rule 110 provides that an amendment, either of form or substance, may be made at any time before the accused enters a plea to the charge and, thereafter, as to all matters of form with leave of court.
What kinds of trials require a EudraCT number?
What is a Susar in clinical trials?
An SAE that occurs during research with a medicinal product may be a SAR or a SUSAR. SAR is the abbreviation for Serious Adverse Reaction, and SUSAR for Suspected Unexpected Serious Adverse Reaction.
Do you need IND before Phase 1?
CLARIFICATIONS OF PRESENT IND REGULATIONS An IND submission for Phase 1 studies is required by regulation to contain the sections enumerated below. Clarifications are described when appropriate beneath each section heading.